A preclinical and clinical study of lithium in low-grade neuroendocrine tumors

Oncologist

Volumn 16, Issue 4, 2011, Pages 452-457

  Lubner, Sam J ^a   Kunnimalaiyaan, Muthusamy ^b   Holen, Kyle D ^a   Ning, Li ^b   Ndiaye, Mary ^b   Loconte, Noelle K ^a   Mulkerin, Daniel L ^a   Schelman, William R ^a   Chen, Herbert ^a,b  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Carcinoid tumors; Chemotherapy; Glycogen synthase kinase 3 ; Lithium chloride; Neuroendocrine tumors

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE;

ABDOMINAL DISCOMFORT; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ARTICLE; CANCER INHIBITION; CANCER OF UNKNOWN PRIMARY SITE; CARCINOID; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENZYME PHOSPHORYLATION; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MOUSE; NEUROENDOCRINE TUMOR; NONHUMAN; OPEN STUDY; OVERALL SURVIVAL; PANCREAS ISLET CELL TUMOR; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREMOR; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM CHLORIDE; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; PHOSPHORYLATION; TREATMENT FAILURE;

EID: 79955570598     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0323     Document Type: Article

References (21)

1. Musunuru S, Chen H, Rajpal S et al. Metastatic neuroendocrine hepatic tumors: Resection improves survival. Arch Surg 2006;141:1000-1004; discussion 1005.
2. Sippel RS, Chen H. Carcinoid tumors. Surg Oncol Clin N Am 2006;15: 463-478.
3. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999;86:944-948.
4. Gonzalez MA, Biswas S, Clifton L et al. Treatment of neuroendocrine tumours with infusional 5-fluorouracil, folinic acid and streptozocin. Br J Cancer 2003;89:455-456.
5. Kouvaraki MA, Ajani JA, Hoff P et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-4771.
6. Moertel CG, Lefkopoulo M, Lipsitz S et al. Streptozocin-doxorubicin, streptozocin-fluorouracil, or chlorozotocin in the treatment of advanced islet- cell carcinoma. N Engl J Med 1992;326:519-523.
7. Ansell SM, Mahoney MR, Green EM et al. Topotecan in patients with advanced neuroendocrine tumors: A phase II study with significant hematologic toxicity. Am J Clin Oncol 2004;27:232-235.
8. Frank M, Klose KJ, Wied M et al. Combination therapy with octreotide and alpha-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol 1999;94:1381-1387.
9. Kulke MH, Stuart K, Enzinger PC et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006;24:401-406.
10. Kunz P, Kuo T, Kaiser H et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary results. Presented at the American Society of Clinical Oncology 2008 Annual Meeting, Chicago, Illinois, May 30-June 3, 2008.
11. Pinchot SN, Holen K, Sippel RS et al. Carcinoid tumors. The Oncologist 2008;13:1255-1269.
12. Saltz L, Kemeny N, Schwartz G, Kelsen D. A phase II trial of alpha interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer 1994;74:958-961.
13. Shah MH, Young D, Kindler HL et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004;10:6111-6118.
14. Yao JC, Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: Results of a phase II study. J Clin Oncol 2008;26:4311-4318.
15. Kulke MH, Lenz HJ, Meropol NJ et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-3410.
16. Raymond E, Raoul J, Niccoli P et al. Phase III, randomized, doubleblind trial of sunitinib versus placebo in patients with progressive, welldifferentiated pancreatic islet cell tumours. Presented at the 11th World Congress on Gastrointestinal Cancer, Barcelona, Spain, June 24-27,2009.
17. Rinke A, Müller HH, Schade-Brittinger C et al. Placebo-controlled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 2009;27:4656-4663.
18. Greenblatt DY, Ndiaye M, Chen H et al. Lithium inhibits carcinoid cell growth in vitro. Am J Transl Res 2010;2:248-253.
19. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA et al. Inactivation of glycogen synthase kinase-3β, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther 2007;6:1151-1158.
20. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem Biophys Res Commun 2001;280: 720-725.
21. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.